High crossreactivity of human T cell responses between Lassa virus lineages

Lassa virus infects hundreds of thousands of people each year across rural West Africa, resulting in a high number of cases of Lassa fever (LF), a febrile disease associated with high morbidity and significant mortality. The lack of approved treatments or interventions underscores the need for an effective vaccine. At least four viral lineages circulate in defined regions throughout West Africa with substantial interlineage nucleotide and amino acid diversity. An effective vaccine should be designed to elicit Lassa virus specific humoral and cell mediated immunity across all lineages. Most current vaccine candidates use only lineage IV antigens encoded by Lassa viruses circulating around Sierra Leone, Liberia, and Guinea but not Nigeria where lineages I-III are found. As previous infection is known to protect against disease from subsequent exposure, we sought to determine whether LF survivors from Nigeria and Sierra Leone harbor memory T cells that respond to lineage IV antigens. Our results indicate a high degree of cross-reactivity of CD8+ T cells from Nigerian LF survivors to lineage IV antigens. In addition, we identified regions within the Lassa virus glycoprotein complex and nucleoprotein that contributed to these responses while T cell epitopes were not widely conserved across our study group. These data are important for current efforts to design effective and efficient vaccine candidates that can elicit protective immunity across all Lassa virus lineages.

[1]  D. Kranz,et al.  T-cell Receptors Engineered De Novo for Peptide Specificity Can Mediate Optimal T-cell Activity without Self Cross-Reactivity , 2019, Cancer Immunology Research.

[2]  Lisa E. Wagar,et al.  Increased T Cell Differentiation and Cytolytic Function in Bangladeshi Compared to American Children , 2019, Front. Immunol..

[3]  P. Lemey,et al.  Phylogeography of Lassa Virus in Nigeria , 2019, Journal of Virology.

[4]  C. Ihekweazu,et al.  A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[5]  S. Gilbert,et al.  Vaccine platforms for the prevention of Lassa fever , 2019, Immunology Letters.

[6]  M. A. Suchard,et al.  Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak , 2019, Science.

[7]  Mayuko Kimura,et al.  Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria , 2018, PLoS neglected tropical diseases.

[8]  Catherine A. Freije,et al.  Genomic analysis of Lassa virus from the 2018 surge in Nigeria , 2018, The New England journal of medicine.

[9]  Brian C. Ware,et al.  Lymphocytic choriomeningitis virus Clone 13 infection causes either persistence or acute death dependent on IFN-1, cytotoxic T lymphocytes (CTLs), and host genetics , 2018, Proceedings of the National Academy of Sciences.

[10]  Karthik Gangavarapu,et al.  Analysis of CD8+ T cell response during the 2013–2016 Ebola epidemic in West Africa , 2018, Proceedings of the National Academy of Sciences.

[11]  B. R. Noack,et al.  New Lineage of Lassa Virus, Togo, 2016 , 2018, Emerging infectious diseases.

[12]  Donald S. Grant,et al.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever , 2017, Nature Medicine.

[13]  Jay B. Varkey,et al.  A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses , 2017, The Journal of infectious diseases.

[14]  K. Chandran,et al.  Structural basis for antibody-mediated neutralization of Lassa virus , 2017, Science.

[15]  Pardis C Sabeti,et al.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits , 2016, Nature Communications.

[16]  S. Günther,et al.  Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever , 2016, PLoS pathogens.

[17]  N. Forrester,et al.  Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage , 2015, Front. Microbiol..

[18]  Elizabeth M. Ryan,et al.  Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus , 2015, Cell.

[19]  L. Moses,et al.  Sequence Variability and Geographic Distribution of Lassa Virus, Sierra Leone , 2015, Emerging infectious diseases.

[20]  C. Ng,et al.  Type I interferon is a therapeutic target for virus-induced lethal vascular damage , 2014, Proceedings of the National Academy of Sciences.

[21]  Mark M. Davis,et al.  Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.

[22]  J. Altman,et al.  Use of replication restricted recombinant vesicular stomatitis virus vectors for detection of antigen-specific T cells. , 2012, Journal of immunological methods.

[23]  D. Price,et al.  A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides* , 2011, The Journal of Biological Chemistry.

[24]  S. Günther,et al.  Current Molecular Epidemiology of Lassa Virus in Nigeria , 2010, Journal of Clinical Microbiology.

[25]  S. Günther,et al.  T Cell-Dependence of Lassa Fever Pathogenesis , 2010, PLoS pathogens.

[26]  N. Tordo,et al.  Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys , 2009, Journal of Virology.

[27]  Bjoern Peters,et al.  The CD8+ T-Cell Response to Lymphocytic Choriomeningitis Virus Involves the L Antigen: Uncovering New Tricks for an Old Virus , 2007, Journal of Virology.

[28]  R. Ahmed,et al.  Quantitating the Magnitude of the Lymphocytic Choriomeningitis Virus-Specific CD8 T-Cell Response: It Is Even Bigger than We Thought , 2006, Journal of Virology.

[29]  B. Mothé,et al.  Development of a New Vaccine for the Prevention of Lassa Fever , 2005, PLoS medicine.

[30]  A. Hoerauf,et al.  Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. , 2004, Virology.

[31]  Alessandro Sette,et al.  Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. , 2003, Virology.

[32]  A. Sette,et al.  In Vivo Selection of a Lymphocytic Choriomeningitis Virus Variant That Affects Recognition of the GP33-43 Epitope by H-2Db but Not H-2Kb , 2001, Journal of Virology.

[33]  Stuart T. Nichol,et al.  Genetic Diversity among Lassa Virus Strains , 2000, Journal of Virology.

[34]  L. Hutwagner,et al.  Effective Vaccine for Lassa Fever , 2000, Journal of Virology.

[35]  A. Hoerauf,et al.  Characterization of Human CD4+ T-Cell Clones Recognizing Conserved and Variable Epitopes of the Lassa Virus Nucleoprotein , 2000, Journal of Virology.

[36]  C Oseroff,et al.  Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. , 1998, Virology.

[37]  J. Sidney,et al.  Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. , 1996, Journal of immunology.

[38]  L. Hutwagner,et al.  Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice , 1995, BMJ.

[39]  M. Oldstone,et al.  Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes , 1995, Journal of virology.

[40]  J. McCormick,et al.  Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys , 1992, Journal of medical virology.

[41]  J. Whitton,et al.  Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus , 1988, Journal of virology.

[42]  S. Fisher-Hoch Lessons from nosocomial viral haemorrhagic fever outbreaks. , 2005, British medical bulletin.